Heart failure & cardiomyopathies
Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status: Insights From the VICTORIA Trial
Authors' conclusion
In this post hoc analysis of VICTORIA, vericiguat compared with placebo significantly reduced the risk of cardiovascular death or HFH in patients with worsening HF with reduced ejection fraction regardless of T2DM status.
Study context
- Population
- Patients with HFrEF enrolled in VICTORIA, stratified by T2DM status3,683 with baseline HbA1c
- Participants
- 5,050 patients
- Comparison
- Vericiguat vs placebo, by baseline T2DM status
- Primary endpoint
- CV death or first heart failure (HF) hospitalization (HFH)
Methodological detailspost hoc analysis
- Post hoc analysis
Primary result
As reported in the abstract
CV death or first HFH, by T2DM subgroup
Vericiguat vs PlaceboHazard ratio (95% CI)
T2DM by history
0.92(0.81–1.04)
T2DM by HbA1c
0.77(0.49–1.20)
pre-T2DM by HbA1c
0.88(0.68–1.13)
Normoglycemia
1.02(0.75–1.39)
Further findings
Baseline glycaemic status (of 3,683 with HbA1c)
- T2DM
- 2,270 (61.6%)
- Pre-T2DM
- 741 (20.1%)
- No T2DM
- 449 (12.2%)
- Undiagnosed T2DM
- 178 (4.8%)
Heart failure hospitalization (HFH), all-cause and CV death by subgroup
- No significant differences in vericiguat efficacy across subgroups
Original publication
Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status: Insights From the VICTORIA Trial. JACC Heart Fail. Published 26 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →